<div id="readability-page-1"><p>J.P. Morgan analyst Casey Woodring reiterated a Buy rating on Repligen yesterday and set a price target of $190.00. The company’s shares closed yesterday at $160.58.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Woodring is an analyst with an average return of <span>-4.0%</span> and a 46.38% success rate. Woodring covers the Healthcare sector, focusing on stocks such as Thermo Fisher, Natera, and BillionToOne, Inc. Class A.</p> <p>Repligen has an analyst consensus of Strong Buy, with a price target consensus of $188.20.</p></div>

RGEN

<p>J.P. Morgan analyst Casey Woodring reiterated a Buy rating on Repligen, setting a price target of $190. The shares closed at $160.58. Woodring, with an average return of -4.0% and a 46.38% success rate, covers the Healthcare sector. Repligen has a Strong Buy consensus with a price target of $188.20.</p>

J.P. Morgan Keeps Their Buy Rating on Repligen (RGEN)